Rheumatoid arthritis is not just joint pain. It is a systemic autoimmune condition that can cause permanent joint damage if left untreated. Early diagnosis and the right treatment are transformative.
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune condition in which the body's immune system mistakenly attacks the lining of the joints — a tissue called the synovium. This causes inflammation, swelling, pain and, if untreated, irreversible joint damage. Unlike osteoarthritis, which is largely a wear-and-tear condition, RA is driven by an overactive immune response and can affect people at any age, including younger adults.
RA is also systemic — meaning it can affect organs beyond the joints, including the lungs, heart, eyes and blood vessels. This is why specialised rheumatological care is essential.
The earliest manifestations of RA are often subtle and easy to dismiss. They include morning stiffness lasting more than an hour, symmetrical joint swelling (affecting the same joints on both sides of the body), tenderness in the small joints of the hands, wrists and feet, persistent fatigue and a general sense of being unwell. These symptoms often fluctuate in the early stages, which can delay diagnosis.
If you are experiencing persistent joint pain or swelling, particularly in the morning, a rheumatological evaluation is warranted. Do not wait for symptoms to become severe before seeking care.
Research has clearly established that the first few months of RA are a critical window. Starting the right treatment early — typically with disease-modifying anti-rheumatic drugs (DMARDs) — can dramatically reduce inflammation, prevent joint damage and preserve long-term function. The damage caused by untreated or inadequately treated RA is cumulative and permanent. The goal of modern rheumatology is remission — the complete suppression of active disease.
The treatment of RA has been transformed over the past two decades. Beyond traditional DMARDs such as methotrexate, biologic therapies — including TNF inhibitors, IL-6 inhibitors and B-cell depleting agents — and targeted synthetic DMARDs now offer effective options for patients who do not respond adequately to conventional treatment.
Selecting the right therapeutic strategy requires detailed assessment of disease activity, severity, comorbidities and patient preferences. This is the domain of a trained rheumatologist — a specialist who can navigate the complexity of modern RA treatment and adjust therapy based on a patient's response over time.
With the right treatment and monitoring, the majority of people with RA can achieve sustained remission or low disease activity and live full, active lives. Regular follow-up with a rheumatologist, adherence to prescribed medications, physiotherapy, occupational therapy and lifestyle modifications all contribute to long-term outcomes.
At RVR Super Speciality Centre, Dr. Sahana G Baliga brings MRCP UK credentials, MRCP SCE Rheumatology certification and three EULAR Fellowships — in Rheumatic Diseases, Imaging in RMDs and Pediatric Rheumatology — to the management of RA and other autoimmune conditions. This standard of expertise is now available in Mangalore.